Alnylam Pharmaceuticals
NasdaqGS:ALNY Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 18 Fair Values set on narratives written by author
AN
Consensus Narrative from 30 Analysts
Vutrisiran And AMVUTTRA Approvals Will Transform The TTR Franchise
Key Takeaways Vutrisiran's approval and AMVUTTRA's anticipated approval in ATTR cardiomyopathy are expected to drive significant revenue and profit growth for Alnylam. New product launches and partnerships with industry leaders position Alnylam for sustainable innovation and increased financial resilience.
View narrativeUS$304.87
FV
16.9% undervalued intrinsic discount28.61%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
Updated narrative